FDA Issues Draft Guidance on Formal Meetings between the FDA and Sponsors or Applicants of BsUFA Products and Classification Categories for Certain Supplements under BsUFA III | Goodwin

In August 2023, the Food and Drug Administration issued two draft guidance, both related to the development of biosimilar products, entitled “Formal Meetings between the FDA and...

Related Keywords

,Product Development ,Drug Administration ,Certain Supplements ,Biosimilar Initial Advisory ,Biological Product Development ,Biosimilar User Fee Amendments ,Safety Information ,Additional Indication ,Without New Data Sets ,With New Data Sets ,Does Not Contain An Up To Date Agreed ,With Efficacy Data Sets ,Initial Determination ,